A Phase I/IIa Open-label Dose Escalation Trial Evaluating the Safety and Preliminary Efficacy of LEU011 in Subjects With Relapsed/Refractory Solid Tumours
Latest Information Update: 12 Jan 2024
At a glance
- Drugs LEU-011 (Primary)
- Indications Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms AERIAL Trial
- Sponsors Leucid Bio
- 21 Dec 2023 Status changed from planning to recruiting.
- 21 Sep 2023 According to Leucid Bio media release, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorisation (CTA) to commence this trial
- 21 Sep 2023 According to Leucid Bio media release, Company is on track to dose first patient in this trial during the fourth quarter of 2023